1. Diagnosis jeung perlakuan munggaran kanker paru
Pasén Lu ieu didiagnosis kalawan adenocarcinoma paru sarta metastasis titik limfa 26. Agustus 2005. A lobectomy handap kénca dipigawé dina 22. September 2005. Carboplatin digabungkeun jeung taxotere dipaké 4 kali sanggeus bedah. Dina 3 Agustus 2007, alatan effusion pleural, diagnosis dikonfirmasi kambuh, sarta anjeunna dirawat kalayan Tarceva (jumlah siklus teu dipikanyaho). Dina 8 Januari 2008, kamajuan kanker kapanggih dina reexamination, lajeng perlakuan Tarceva dieureunkeun sarta perlakuan Libita dimimitian pikeun 16 siklus. Dina waktu nu sarua, metastasis hip vertebral kapanggih sarta 4 siklus Zetai dipigawé.
2. Pertama kali pikeun ilubiung dina percobaan klinis, kaayaan téh dina kontrol.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Dina sidang klinis kadua, tumor nu ngiles écés.
On August 6, 2012, Mr. Lu participated in the AP26113 drug sidang klinis at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumor dina uteuk decreased and became large.
4. Panggihan mutations gén langka tur ngarepkeun ilubiung dina percobaan klinis anyar
Ujian ulang dina bulan Juli 2014, PET sakabeh awak némbongkeun: Lesions otak dasarna stabil, jeung dada geus jelas kamajuan. Dina 12 Méi 2014, anu disangka anti-AP26113 limfa (3 sél, pangbadagna 1.1 cm) garis sél berbudaya dilaksanakeun di Rumah Sakit Umum Massachusetts sarta terus nyandak AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
